By Stephen Nakrosis DBV Technologies said it received requested feedback from the U.S. Food and Drug Administration for a pair of supplemental safety studies.
StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a research note issued to investors on Saturday. The firm issued a sell rating on the stock. A number of other analysts have also recently weighed in on the company. HC Wainwright restated a buy rating and issued a $10.00 price target […]
StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a research note published on Saturday. The firm issued a sell rating on the stock. Several other research analysts have also commented on DBVT. HC Wainwright reaffirmed a buy rating and issued a $10.00 price target on shares of DBV Technologies in […]
DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) Director Timothy E. Morris acquired 12,000 shares of DBV Technologies stock in a transaction dated Friday, August 25th. The shares were bought at an average cost of $1.52 per share, for a total transaction of $18,240.00. Following the completion of the purchase, the director now directly owns […]